

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Hiroki Kuyama et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: METHOD OF ELIMINATING PHOSPHATE
GROUP OF PEPTIDE AND METHOD OF
ANALYZING PEPTIDE

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Submitted herewith on Form PTO-1449 or PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR 1.56. Applicant respectfully requests that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of Form PTO-1449 or PTO/SB/08 be returned in accordance with MPEP §609.

- ☒ A copy of each listed document is being submitted to comply with the provisions of 37 CFR §§1.97 and 1.98
- ☐ As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously cited by or submitted to the Patent Office in parent application Serial No. _____, filed _____.
- ☒ A copy of each listed document, that was cited in the International Search Report or International Preliminary Examination Report attached hereto, should have been provided to the U.S. Patent and Trademark Office by the WIPO, and the provisions of 37 CFR §§1.97 and 1.98 should have been complied with.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.


Application No.: Not Yet Assigned

Docket No.: OKA-0226

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date or within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in compliance with 37 C.F.R. §1.97(b), OR is being filed concurrent with filing of the Continued Prosecution Application (CPA) or the Request for Continued Examination (RCE). No fee is required (37 C.F.R. §1.97(b)). A summary/abstract translation of the non-English language references is enclosed.
- ☒ 2. Please charge any fee deficiency or credit any overpayment to Deposit Account No. 18-0013 as needed

Dated: April 14, 2005

Respectfully submitted,



By David T. Nikaido

Registration No.: 22,663

RADER, FISHMAN & GRAUER PLLC

1233 20th Street, N.W., Suite 501

Washington, DC 20036

(202) 955-3750

Attorney for Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Hiroki Kuyama
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	OKA-0226
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-01/078106-A2	10-18-2001	Perceptive Biosystems, Inc.		✓
	BB	GB-2 000 511-A	01-10-1979	F. Hoffmann-La Roche & Co Akitengesellschaft		✓
	BC	JP-10-090226-A1	04-10-1998	Shimadzu Corporation		✓

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	PCT International Search Report for PCT/JP03/04305 mailed on July 15, 2003.	
	CB	Mark A. Smith et al., "Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease", Brain Research, 1996, Vol. 717, pages 99-108, Elsevier Science Publishers B.V.	
	CC	Jose M. Merchero, et al., "Quantum Mechanical Calculations on Phosphate Hydrolysis Reactions", Journal of Computational Chemistry, 2000, Vol. 21, No. 1, pages 43-51, John Wiley & Sons, Inc.	
	CD	Timothy O'Hare, et al., "Intrinsic Kinase Activity of the Insulin Receptor", The Journal of Biological Chemistry, 1989, Vol. 264, No. 1, pages 602-610, The American Society for Biochemistry and Molecular Biology, Inc.	
	CE	Peter White, "Optimization of Coupling Methods for the Introduction of Mono-Benzyl Phosphate Esters of Fmoc Protected Phosphoamino Acids", Peptides: The Wave of the Future, Michal Lebl and Richard A. Houghten (Editors), American Peptide Society, 2001, pages 97-98.	
	CF	Ann M. Edison, et al., "Exploration of the Sequence Specificity of pp 60c-src Tyrosine Kinase", The Journal of Biological Chemistry, 1995, Vol. 270, No. 45, issue of November 10, 1995, pages 27112-27115.	
	CG	Elaine Fuchs, et al., "The Use of Hydrofluoric Acid in the Identification of Lipid Intermediates in Peptidoglycan Synthesis", Analytical Biochemistry, 1978, Vol. 90, pages 465-473, Academic Press, Inc.	
	CH	Chi-Jen Lee, et al., "The Structures of the Cross-Reactive Types 19 (19F) and 57 (19A) Pneumococcal Capsular Polysaccharides", The Journal of Biological Chemistry, Vol. 225, No. 14, Issue of July 25 1980, pages 6847-6853.	
	CI	Lawrence R. Phillips, et al., "The Structure of the Repeating Oligosaccharide Unit of the Pneumococcal Capsular Polysaccharide Type 18C", Carbohydrate Research, 1983, Vol. 121, pages 243-255, Elsevier Science Publishers B.V.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--